Drug Development

A Belgian firm's new biologic gel for diabetic foot ulcers gets a key FDA green light, offering hope against a leading cause of amputations.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

OncLive® unveils its 2026 class of inductees, 14 visionaries whose groundbreaking work is transforming the future of oncology and bringing hope to millions.

UWorld and the Goldwater Foundation award 93 top students, fueling the pipeline of medical researchers poised to tackle society's biggest health challenges.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

A new obesity drug shows 19.3% weight loss with remarkably few side effects, while also improving blood pressure, cholesterol, and even bone density.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

At the elite FiRe 2026 conference, Pattern Computer plans to unveil a 'hallucination-free' AI, promising a new era of scientific discovery and trust.

Medcura adds a Johnson & Johnson heavyweight to its board, aiming to disrupt the surgical hemostasis market with its FDA-designated breakthrough gel, LifeGel.

Imviva Biotech's new CAR-T therapy shows potential for durable remission in lupus, moving advanced cell treatments beyond cancer to autoimmune disease.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

Anika Therapeutics posts strong Q1 results with a 13% revenue jump, but analyst caution lingers over pipeline risks and long-term sustainability.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

By emphasizing deep anatomical knowledge, Medytox aims to elevate industry standards and solidify its leadership in Asia's booming medical aesthetics market.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

With the hire of world-renowned surgeon Dr. Nelson Oyesiku, Piedmont Healthcare signals its ambition to become a top destination for neurological care in the Southeast.

Following a breakthrough in chondrosarcoma, Inhibrx Biosciences is set to reveal pivotal data for its drug ozekibart in the vast colorectal cancer market.